Stroke drug bleeding risks revealed in new study

NCT ID NCT06337175

Completed Knowledge-focused Sponsor: Kafrelsheikh University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study in 600 stroke patients in the Middle East looked at what factors might predict different types of brain bleeding after treatment with the clot-busting drug alteplase. Researchers analyzed patient characteristics, how quickly the drug was given, and stroke risk factors to see which ones were linked to bleeding. The goal was to better understand who is at higher risk, which could help doctors make safer treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alteplase (a clot-busting drug)
What this could lead to: If successful, this could help doctors identify which stroke patients are at higher risk of brain bleeding after receiving alteplase, potentially improving treatment safety.
What could go wrong: This is a completed observational analysis, not a new treatment trial. The findings may not apply to all populations or change current guidelines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALTEPLASE ADVERSE REACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALTEPLASE ADVERSE REACTION ISCHEMIC STROKE

Contacts and locations

Locations

Kafr Elsheikh University Hospital

Kafr ash Shaykh, 33155, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.